VEGFA and non-small cell lung carcinoma: It has been demonstrated that the combination of chemotherapy plus anti-angiogenesis based therapy such as bevacizumab, a recombinant humanized monoclonal antibody against vascular endothelial growth factor A (VEGF-A), increased the response rate and progression-free survival of patients with NSCLC [25, 26].